Green Hygienics Holdings Collaborates with Cinvestav to Develop Cannabinoid-based Products Targeting Endocannabinoid System (ECS) Deficiencies

Green Hygienics Holdings Inc. (GRYN) agrees to a contract with Cinvestav, a leading Mexican academic research institution, to move forward with their research targeting the endocannabinoid system (ECS) deficiencies.

FREMONT, CA: Green Hygienics Holdings Inc. (GRYN) enters into a scientific research collaboration agreement with Cinvestav, the Center for Research and Advanced Studies of the National Polytechnic Institute (Centro de Investigaci³n y de Estudios Avanzados del Instituto Polit©cnico Nacional).

The institute, a top-ranked multidisciplinary Mexican scientific research institution, will work with Green Hygienics to support R&D efforts in developing cannabinoid-based products that target the ECS deficiencies in animals and humans. Cinvestav ranks fourth in Latin America and 118th in the world.

Dr. Luisa Lilia Rocha Arrieta, Ph.D., M.D., a top research investigator at the Department of Pharmacology at Cinvestav, says, “The treatment of chronic pain has relied heavily on opioids, despite their potential for addiction, overdose and the fact that they often dont work well when used on a long-term basis. There’s an urgent need for more effective and safer options. These new collaborative research projects, like we’ve established with Green Hygienics, will investigate substances derived from hemp that dont have psychoactive disadvantages, looking at their basic biological activity and their potential mechanisms of action as endocannabinoid system (ECS) modulators.”

“This research collaboration will be our first project under TruLife Biotech LLC, a Green Hygienics Company focused on the development and advancement of innovative cannabinoid-based nutraceutical and skincare products and brands," states Dr. Levan Darjania, chief scientific officer of Green Hygienics. "The collaboration with Cinvestav will augment ongoing efforts by both parties to identify and explore selected cannabinoids and terpenes in planned combinations that may act synergistically to protect against pain development and determine their potential efficacy as pain relievers against inflammatory and neuropathic pain. Therefore, the Company is building its collaborative model with academic institutions and will utilize its TruLife Biotech R&D platform to create proprietary and highly efficacious cannabinoid-based products.”

"Discovery and development of cannabinoid-based products that are truly effective in producing a desired result are global tasks that are based on multidisciplinary approaches, collaborations, and partnerships. After meeting with leading researchers at Cinvestav's Mexico City Campus, we are confident in our collaboration on the development of new and efficacious products," states Kyle. "Offering researched-backed products that actually work for their intended purpose will lead us to stay ahead of the curve of regulatory approval, allow our products to stand apart from the competition, and is the fastest and most cost-efficient way to expand into new markets.” MacKinnon, COO of Green Hygienics, concludes.